Table 1. Summary of the Four Double-Blind, Placebo-Controlled Duloxetine Studies in Patients with MDD Included in the Pooled Analysis.
STUDY | TREATMENT DURATION | DRUG | PATIENTS | DRUG DOSE AND DESIGN |
---|---|---|---|---|
1 | 8 weeks | Placebo | 90 | – |
(Nemeroff 2002) | Duloxetine | 91 | 40 mg/day (20 mg b.i.d.) | |
Duloxetine | 84 | 80 mg/day (40 mg b.i.d.) | ||
Paroxetine | 89 | 20 mg/day (q.d.) | ||
2 | 8 weeks | Placebo | 89 | – |
(Goldstein 2004) | Duloxetine | 86 | 40 mg/day (20 mg b.i.d.) | |
Duloxetine | 91 | 80 mg/day (40 mg b.i.d.) | ||
Paroxetine | 87 | 20 mg/day (q.d.) | ||
3 | 8 weeks | Placebo | 93 | – |
(Detke 2004) | Duloxetine | 93 | 80 mg/day (40 mg b.i.d.) | |
Duloxetine | 93 | 120 mg/day (60 mg b.i.d.) | ||
Paroxetine | 85 | 20 mg/day (q.d.) | ||
4 | 8 weeks | Placebo | 99 | – |
(Perahia 2006) | Duloxetine | 93 | 80 mg/day (40 mg b.i.d.) | |
Duloxetine | 102 | 120 mg/day (60 mg b.i.d.) | ||
Paroxetine | 97 | 20 mg/day (q.d.) |
b.i.d., twice daily; MDD, major depressive disorder; q.d., once daily.